Starring role of Biomarkers and Anticancer Agents as a Major Driver in Precision Medicine of Cancer Therapy

Abstract

: Precision medicine represents the most modern contemporary medicine trend, based on enormous amounts of data relating to people's health, individual characteristics, and life context using the most appropriate strategies to prevent and cure them. Precision medicine in cancer coordinates most precisely and viable treatment to every individual cancer patient based on the disease's genetic profile. Precision medicine changes the standard one size fits all medication model, which has focused on average responses to care. Significantly, consolidating different modern methodologies for streamlining and checking anticancer drugs can have continuous effects on understanding results. Precision medicine can help explicit anticancer treatments using various drugs and even in discovery, thus becoming the paradigm of future cancer medicine. Cancer biomarkers are a significant focus point in precision medicine, and findings of different biomarkers make this field more promising and challenging. Naturally, genetic instability and the collection of extra changes in malignant growth cells are ways that cancer cells use to adapt and survive in a hostile environment, for example, one made by these treatment modalities. Precision medicine is centered around recognizing which treatments are best for individual patients, dependent on their malignant growth and genetic characterization. This new era of genomics, which is progressively referred to as precision medicine, has ignited a new episode in the relationship between genomics and anticancer drug development.